StockNews.com Initiates Coverage on Oragenics (NYSE:OGEN)

Stock analysts at StockNews.com assumed coverage on shares of Oragenics (NYSE:OGEN) in a research note issued on Thursday. The firm set a “sell” rating on the stock.

Oragenics Stock Performance

Shares of OGEN opened at $0.29 on Thursday. The stock has a market cap of $3.57 million, a PE ratio of -0.04 and a beta of 0.49. Oragenics has a fifty-two week low of $0.25 and a fifty-two week high of $7.74. The firm’s 50-day simple moving average is $0.35 and its two-hundred day simple moving average is $0.98.

Institutional Investors Weigh In On Oragenics

A hedge fund recently bought a new stake in Oragenics stock. Virtu Financial LLC purchased a new stake in shares of Oragenics, Inc. (NYSE:OGEN) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned about 0.51% of Oragenics as of its most recent SEC filing. 18.71% of the stock is owned by institutional investors and hedge funds.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.